Seagen and astellas announce submission of two supplemental biologics license applications to the u.s. fda for padcev® (enfortumab vedotin-ejfv) in locally advanced or metastatic urothelial cancer

Bothell, wash. & tokyo--(business wire)--seagen inc. (nasdaq:sgen) and astellas pharma inc. (tse: 4503, president and ceo: kenji yasukawa, ph.d., “astellas”) today announced completion of submissions for two supplemental biologics license applications (sblas) to the u.s. food and drug administration (fda) for padcev® (enfortumab vedotin-ejfv). one submission, based on the phase 3 ev-301 trial, seeks to convert padcev's accelerated approval to regular approval. the second submission, based on th
SGEN Ratings Summary
SGEN Quant Ranking